Enzalutamide: An evidence-based review of its usein the treatment of prostate cancer

Core Evidence

Volumn 8, Issue , 2013, Pages 27-35

  Golshayan, Ali R ^a   Antonarakis, Emmanuel S ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Androgen receptor; Antiandrogen; Castration resistant prostate cancer; Enzalutamide; MDV3100

Indexed keywords

ABIRATERONE; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR ANTAGONIST; ARN 509; BICALUTAMIDE; CABAZITAXEL; DOCETAXEL; DUTASTERIDE; ENZALUTAMIDE; LEUPRORELIN; MITOXANTRONE; RADIUM; RADIUM 223; SIPULEUCEL T; UNCLASSIFIED DRUG;

ASTHENIA; BACKACHE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CAUDA EQUINA SYNDROME; CELL NUCLEUS; CYTOPLASM; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EVIDENCE BASED PRACTICE; FATIGUE; GENE TRANSLOCATION; GENETIC TRANSCRIPTION; HEADACHE; HEMATURIA; HOT FLUSH; HUMAN; HYPERTENSION; INSOMNIA; LOWER RESPIRATORY TRACT INFECTION; MEDICAL LITERATURE; MEDLINE; MODULATION; MUSCLE WEAKNESS; MUSCULOSKELETAL PAIN; NONHUMAN; OVERALL SURVIVAL; PARESTHESIA; PEER REVIEW; PROSTATE CANCER; REVIEW; SEIZURE; SPINAL CORD COMPRESSION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

EID: 84876265987     PISSN: 15551741     EISSN: None     Source Type: Journal    
DOI: 10.2147/CE.S34747     Document Type: Review

References (30)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Iversen P, McLeod DG, See WA, et al. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. BJU Int. 2010;105:1074-1081.
3. Tyrrell CJ, Kaisary AV, Iversen P, et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol. 1998;33:447-456. (Pubitemid 28251992)
4. Samson DJ, Seidenfeld J, Schmitt B, et al. Systematic review and metaanalysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer . 2002;95: 361-376. (Pubitemid 34787603)
5. Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer. 1995;76:1428-1434.
6. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science . 2009;324:787-790.
7. Li Y, Chan SC, Brand LJ, et al. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 2012;73:483-489.
8. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study. Lancet. 2010;375:1437-1446.
9. Higano C, Beer TM, Taplin M, et al. Antitumor activity of MDV3100 in pre- and post-docetaxel advanced prostate cancer: Long-term follow-up of a phase 1-2 study. J Clin Oncol. 2011;29(7):abstract 134.
10. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367: 1187-1197.
11. Fizazi K, Scher HI, Saad F, et al. Impact of enzalutamide, an androgen receptor signaling inhibitor, on time to first skeletal related event (SRE) and pain in the phase 3 AFFIRM study. 37th European Society for Medical Oncology Congress; September 28-October 2, 2012; Vienna, Austria. Abstract 896O.
12. Scher HI, Fizazi, K, Saad F, et al. Association of baseline corticosteroid with outcomes in a multivariate analysis of the Phase 3 AFFIRM study of enzalutamide (ENZA), an androgen receptor signaling inhibitor. 37th European Society for Medical Oncology Congress; September 28 October 2, 2012. Vienna, Austria. Abstract 899PD.
13. Li Y, Chan SC, Brand LJ, et al. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 2013;73:483-489.
14. Efstathiou E, Titus MA, Tsavachidou A, et al. MDV3100 effects on androgen receptor (AR) signaling and bone marrow testosterone concentration modulation: A preliminary report. J Clin Oncol. 2011;29:abstract 4501.
15. McCourt C, Maxwell P, Mazzucchelli R, et al. Elevation of c-FLIP in Castrate-Resistant Prostate Cancer Antagonizes Therapeutic Response to Androgen Receptor-Targeted Therapy. Clin Cancer Res. 2002;18: 3822-3833.
16. Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509: A novel antiandrogen for prostate cancer treatment. Cancer Res. 2012;72:1494-1503.
17. Rathkopf D, Morris MJ, Danila DC, et al. A phase I study of the androgen signaling inhibitor ARN-509 in patients with metastatic castrationresistant prostate cancer (mCRPC). J Clin Oncol. 2012;30:abstract 4548.
18. Rathkopf D, Danila DC, Morris M, Slovin S, Scher HI. Phase I/II safety and pharmacokinetic (PK) study of ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase I results of a Prostate Cancer Clinical Trials Consortium study. J Clin Oncol. 2012;30(5):abstract 43.
19. Rathkopf D, Shore N, Antonarakis ES, et al. A phase II study of the androgen signaling inhibitor ARN-509 in patients with castrationresistant prostate cancer (CRPC). J Clin Oncol . 2012;30:abstract TPS4697.
20. Baskin-Bey ES, Shore ND, Barber K, Taoufik O, Heidenreich A. TERRAIN: A randomized, double-blind, phase II study comparing MDV3100 with bicalutamide (Bic) in men with metastatic castrateresistant prostate cancer (CRPC). J Clin Oncol . 2012;30:abstract TPS4698.
21. Baskin-Bey ES, Holtkamp GM, Smith MR, et al. A phase II, open-label, single-arm, efficacy, and safety study of MDV3100 in patients with hormone-naïve prostate cancer. J Clin Oncol. 29, 201129(7):abstract 177.
22. Montgomery RB, Joshua A, Hannah AL, et al. A randomized, open- label,phase II study of MDV3100 alone or in combination with leuprolide and dutasteride as neoadjuvant therapy to prostatectomy in intermediate and high-risk prostate cancer. J Clin Oncol. 2012;30: abstract TPS4695.
23. Ryan CJ, Halabi S, Ou SS, Vogelzang NJ, Kantoff P, Small EJ. Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study. Clin Cancer Res. 2007;13: 2030-2037. (Pubitemid 46649869)
24. Richards J, Lim AC, Hay CW, et al. Interactions of abiraterone, eplerenone,and prednisolone with wild-type and mutant androgen receptor: A rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res. 2012;72:2176-2182.
25. Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26:242-245.
26. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet. 2010;376:1147-1154.
27. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2101;363: 411-422.
28. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364: 1995-2005.
29. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368: 138-148.
30. Parker C, Nilsson S, Heinrich E. Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). J Clin Oncol. 2012;30:abstract LBA4512.